Imatinib mesylate (Gleevec), a small molecule inhibitor for several tyrosine kinase receptors, including c-Kit, has shown efficacy in gastrointestinal cancer and acute lymphoblastic leukemia linked to c-Kit S476I and P551A mutations. The gene discussed is KIT; the disease is acute lymphoblastic leukemia.